Bolt Biotherapeutics Management
Management criteria checks 1/4
Bolt Biotherapeutics' CEO is Willie Quinn, appointed in May 2020, has a tenure of 4.67 years. total yearly compensation is $912.18K, comprised of 48.4% salary and 51.6% bonuses, including company stock and options. directly owns 0.095% of the company’s shares, worth $21.12K. The average tenure of the management team and the board of directors is 0.7 years and 2.6 years respectively.
Key information
Willie Quinn
Chief executive officer
US$912.2k
Total compensation
| CEO salary percentage | 48.4% |
| CEO tenure | 4.7yrs |
| CEO ownership | 0.09% |
| Management average tenure | less than a year |
| Board average tenure | 2.6yrs |
Recent management updates
Recent updates
We Think Bolt Biotherapeutics (NASDAQ:BOLT) Needs To Drive Business Growth Carefully
Nov 30
Little Excitement Around Bolt Biotherapeutics, Inc.'s (NASDAQ:BOLT) Revenues As Shares Take 29% Pounding
May 21We Think Bolt Biotherapeutics (NASDAQ:BOLT) Needs To Drive Business Growth Carefully
Mar 15Is Bolt Biotherapeutics (NASDAQ:BOLT) In A Good Position To Deliver On Growth Plans?
May 13Is Bolt Biotherapeutics (NASDAQ:BOLT) In A Good Position To Deliver On Growth Plans?
Dec 01Bolt Biotherapeutics: A Promised Follow Up
Aug 26Bolt Biotherapeutics GAAP EPS of -$0.61 beats by $0.08, revenue of $1.39M beats by $0.89M
Aug 10We're Keeping An Eye On Bolt Biotherapeutics' (NASDAQ:BOLT) Cash Burn Rate
Jul 27We're Not Very Worried About Bolt Biotherapeutics' (NASDAQ:BOLT) Cash Burn Rate
Apr 12We Think Bolt Biotherapeutics (NASDAQ:BOLT) Can Afford To Drive Business Growth
Dec 03Bolt Biotherapeutics: Pioneering A New Class Of Immunotherapies
Aug 18We're Hopeful That Bolt Biotherapeutics (NASDAQ:BOLT) Will Use Its Cash Wisely
Aug 18CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$65m |
| Jun 30 2024 | n/a | n/a | -US$66m |
| Mar 31 2024 | n/a | n/a | -US$63m |
| Dec 31 2023 | US$912k | US$442k | -US$69m |
| Sep 30 2023 | n/a | n/a | -US$71m |
| Jun 30 2023 | n/a | n/a | -US$77m |
| Mar 31 2023 | n/a | n/a | -US$81m |
| Dec 31 2022 | US$1m | US$423k | -US$88m |
| Sep 30 2022 | n/a | n/a | -US$95m |
| Jun 30 2022 | n/a | n/a | -US$97m |
| Mar 31 2022 | n/a | n/a | -US$98m |
| Dec 31 2021 | US$2m | US$395k | -US$99m |
| Sep 30 2021 | n/a | n/a | -US$102m |
| Jun 30 2021 | n/a | n/a | -US$89m |
| Mar 31 2021 | n/a | n/a | -US$77m |
| Dec 31 2020 | US$1m | US$239k | -US$61m |
Compensation vs Market: Willie's total compensation ($USD912.18K) is above average for companies of similar size in the US market ($USD641.95K).
Compensation vs Earnings: Willie's compensation has been consistent with company performance over the past year.
CEO
Willie Quinn (53 yo)
4.7yrs
Tenure
US$912,175
Compensation
Mr. William P. Quinn, also known as Willie, is CEO, President & Director of Bolt Biotherapeutics, Inc. from May 15, 2024. He has been Chief Financial Officer at Bolt Biotherapeutics, Inc. since May 2020 an...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, CFO | 4.7yrs | US$912.18k | 0.095% $ 21.1k | |
| Chief Operating Officer | less than a year | US$839.50k | 0.023% $ 5.2k | |
| VP of Finance & Principal Accounting Officer | less than a year | no data | 0.030% $ 6.6k | |
| VP & Head of Human Resources | 3.7yrs | no data | no data | |
| Senior Vice President of Pharmaceutical Operations | 2.6yrs | no data | no data | |
| Senior Vice President of Clinical Development | less than a year | no data | no data | |
| Senior Vice President of Research | less than a year | no data | no data |
0.7yrs
Average Tenure
53yo
Average Age
Experienced Management: BOLT's management team is not considered experienced ( 0.7 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, CFO | less than a year | US$912.18k | 0.095% $ 21.1k | |
| Independent Director | 4.1yrs | US$80.59k | 0.0031% $ 699.9 | |
| Independent Director | 3.1yrs | US$75.59k | 0% $ 0 | |
| Independent Chairman | 3.2yrs | US$83.09k | 0% $ 0 | |
| Director | less than a year | no data | no data | |
| Independent Director | 2.1yrs | US$65.59k | 0% $ 0 |
2.6yrs
Average Tenure
57yo
Average Age
Experienced Board: BOLT's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/08 08:15 |
| End of Day Share Price | 2025/01/08 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Bolt Biotherapeutics, Inc. is covered by 6 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael Schmidt | Guggenheim Securities, LLC |
| Edward White | H.C. Wainwright & Co. |
| Soumit Roy | JonesTrading Institutional Services, LLC |